In recent years, the debate over net price transparency (NPT) has intensified with organisations leading calls for greater transparency of net prices in the pharmaceutical sector. In a study funded by Merck Sharp & Dohme, an expert panel coordinated by CRA developed evidence on the impact of greater NPT on innovative medicines in Europe.
Keytruda LoE: Does it end or exacerbate the combination pricing problem?
Achieving price solutions for combination regimens that are mutually acceptable to both industry and payers in global healthcare systems, is a challenge that...